Secondary Logo

Journal Logo

Audiological Management of Pediatric Oncology Patients

Sprouse, Brittney AuD; Gozdecki, Michelle Ketcham AuD

doi: 10.1097/01.HJ.0000579572.29927.bc
Pediatric Audiology
Free

Dr. Sprouse, left, is the director of audiology and a pediatric audiologist at University of Chicago Medicine, where her clinical interests include electrophysiology, cochlear implants, ototoxicity monitoring, and working with children with craniofacial syndrome, condition, and/or anomaly. She also serves as the president of the Illinois Academy of Audiology. Dr. Gozdecki is a pediatric audiologist at the University of Chicago Medicine, where her clinical interests include diagnostic evaluations, amplification, and cochlear implants.

The National Cancer Institute estimated 15,590 children and adolescents ages 0-19 were diagnosed with cancer in 2018. In comparison with the past 20 years, the overall childhood cancer survival rate continues to rise. In fact, over 429,000 U.S. childhood cancer survivors were reported to be alive in 2015. Children diagnosed with high-risk cancers are considered medically complex and seen routinely for ototoxicity monitoring. However, barriers can continue to arise throughout and beyond their course of cancer treatment. With an increased incidence of childhood cancer and aggressive medical management, children diagnosed with cancer are at risk for decreased quality of life. Several barriers impact this population, including hearing loss due to ototoxicity, impact of hearing loss on speech and language, school reintegration, and parent coping mechanisms. As audiologists, we play an integral part in the multidisciplinary approach to advocate for treatment options that will help patients overcome these barriers and have a better quality of life.

Figure.

Figure.

Table 1

Table 1

Figure 1.

Figure 1.

Back to Top | Article Outline

OTOTOXIC HEARING LOSS

Ototoxic hearing loss occurs when chemotherapeutic agents cause degeneration of hair cells. Sensorineural hearing loss (SNHL) due to ototoxicity is more often bilateral and symmetrical, originating in the higher frequencies. This can be progressive with an increasing cumulative dose. Platinum-based chemotherapy agents such as cisplatin and carboplatin are common treatment regimens for pediatric cancers, including neuroblastoma, hepatoblastoma, and medulloblastoma. Cisplatin tends to be more ototoxic, although carboplatin can cause significant hearing loss at higher doses. Platinum-based therapy coupled with cranial irradiation has a higher risk of hearing loss, but this requires the hearing mechanism to be within the radiation field.1 Research has shown that children under 5 years old are 21 times more likely to develop moderate to severe high-frequency hearing loss than older children given the same cumulative dose.2

Back to Top | Article Outline

IMPACT ON SPEECH AND LANGUAGE

Speech production and language development require children to be able to perceive and differentiate sounds at all frequencies. Ototoxic hearing loss negatively impacts the high frequency speech sounds s, f, th, sh, h, k, and t. These high-frequency speech sounds account for approximately 50 percent of the consonant sounds in the English language.3 Reduction in the audibility of these consonants impact pre-, peri-, and post-lingual children. Pre- and perilingual children often experience articulation errors, unintelligible speech, a decrease in low-frequency speech cues, plus difficulty with tenses, plurals, and possessives. Children with pre-existing speech and language skills may appear to be less affected by high-frequency hearing loss. However, minimal hearing loss can significantly alter language development, verbal abilities, and reasoning skills of young children.1,4 According to Bass, et al., 37 percent of children with minimal hearing loss fail at least one grade in school compared with the normative rate of three percent.5

Back to Top | Article Outline

SCHOOL REINTEGRATION

The concerns of the student, parents, or teacher can affect a child's re-entry to school after a cancer diagnosis. Table 1 identifies common concerns of the child (student), parent, and teacher when preparing for the child's reintegration into school. About 11 percent of children diagnosed with cancer in childhood or adolescence have school phobia compared with 1.7 percent of the population at large.6 These challenges may occur during or after treatment. When a child can make a prompt return to school, having social support from teachers and classmates can help improve his or her self-esteem and reduce depression and anxiety.6,7

Back to Top | Article Outline

PARENT COPING MECHANISMS

Parents of a child diagnosed with cancer need to cope with the diagnosis and be the child's primary support system. Children are affected by their parent's coping behavior. Parents who have a strong family support system, positive marital relationship, optimistic behavior, reduced concurrent stressors, and open communication are associated with good coping outcomes among childhood cancer survivors.6 Similarly, poor parental coping mechanisms are associated with poor outcomes of young cancer patients. Parent behaviors—such as agitation, stress, anxiety, denial, criticism, apology, and high levels of reassurance during or after painful medical procedures—lead to higher levels of patient distress.6 Physicians advocate for an honest and direct approach in communicating with patients, even at a young age. Evidence shows a more positive adjustment in patients who are informed about their diagnosis. These patients, even those who are young, show lower levels of anxiety about treatments, less defensive posture, closer relationships with parents and caregivers, lower psychological distress, and basic satisfaction with the self.6

Back to Top | Article Outline

ADDRESSING BARRIERS

Outside the standard audiologic interventions (i.e., hearing aids and cochlear implants), numerous solutions are available to help health care providers manage these barriers with patients and their families. Adopting a multidisciplinary team approach can help during diagnosis, treatment, and follow-up. The treatment team should include physicians, social workers, therapists (including a speech-language pathologist, occupational therapist, physical therapist), audiologists, and educational liaisons. With this multidimensional approach, the providers can focus on treating the patient while ensuring that the patient's quality of life is supported.8

The American Society for Clinical Oncology and the American College of Surgeons have recommended integrating early palliative care into standard therapy to improve patient's quality of life, for both adults and children.8 Palliative care is frequently confused with end-of-life and hospice care, but this specialized medical care plays a larger role in managing all chronic disease states, not just terminal illness. Palliative services include, but are not limited to, symptom control, psycho-social support, and impairment-driven rehabilitation measures. Palliative care promotes emotional and physical functions, and supports quality of life across the chronic disease continuum affecting both adults and pediatric patients. It also includes psychosocial and rehabilitation services. Figure 1 shows a multidisciplinary team approach with integrated palliative care services to help balance the need for survival prolonging therapies and improved quality of life.8

As pediatric cancer treatment continues to improve—with patients living longer with their chronic illnesses or being cured altogether—young cancer patients and their families need additional support when reintegrating into the community post-treatment. From an audiological perspective, the main barriers to a successful recovery include ototoxic hearing loss, the impact of hearing loss on speech and language, school reintegration, and parent coping mechanisms. Aside from a referral to audiology and ENT services for standard hearing loss interventions, establishing a multidisciplinary team to also include other physician specialties, social workers, therapists, and educational liaisons helps to improve the quality of life for patients and their caregivers.

Back to Top | Article Outline

REFERENCES

1. Brooks, Beth, and Kristin Knight. “Ototoxicity Monitoring in Children Treated with Platinum Chemotherapy.” International Journal of Audiology, vol. 57, no. sup4, 2017, pp. S62-S68., doi:10.1080/14992027.2017.1355570.
2. Li, Y., Womer, R.B. & Silber, J.H 2004. Predicting cisplatin ototoxicity in children: The influence of age and the cumulative dose. Eur J Cancer, 40, 2445-2451.
3. Knight, Kristin R. Gilmer, et al. “Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development.” Journal of Clinical Oncology, vol. 23, no. 34, 26 Aug. 2005, pp. 8588-8596., doi:10.1200/jco.2004.00.5355.
4. Gurney, J. G., et al. “Hearing Loss, Quality of Life, and Academic Problems in Long-Term Neuroblastoma Survivors: A Report From the Children's Oncology Group.” Pediatrics, vol. 120, no. 5, 2007, pp. e1229-e1236., doi:10.1542/peds.2007-0178.
5. Bass, Johnnie K, et al. “Monitoring Ototoxicity in the Pediatric Oncology Population.” Monitoring Ototoxicity in the Pediatric Oncology Population, American Speech-Language-Hearing Association, June 2013, www.asha.org/articles/monitoring-ototoxicity-in-the-pediatric-oncology-population/.
6. Suzuki, Lalita K., and Pamela M. Kato. “Psychosocial Support for Patients in Pediatric Oncology: The Influences of Parents, Schools, Peers, and Technology.” Journal of Pediatric Oncology Nursing, vol. 20, no. 4, July 2003, pp. 159-174., doi:10.1177/1043454203254039.
7. Thompson, Amanda L., et al. “Academic Continuity and School Reentry Support as a Standard of Care in Pediatric Oncology.” Pediatric Blood & Cancer, vol. 62, no. S5, 20 Aug. 2015, pp. S805-S817., doi:10.1002/pbc.25760.
8. Parikh, Ravi B., et al. “Advancing a Quality-of-Life Agenda in Cancer Advocacy.” JAMA Oncology, vol. 1, no. 4, 2015, p. 423., doi:10.1001/jamaoncol.2015.0925.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.